학술논문

Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions.
Document Type
Article
Source
Multiple Sclerosis Journal. Dec2022, Vol. 28 Issue 14, p2294-2298. 5p.
Subject
*IRON
*MULTIPLE sclerosis
*MAGNETIC resonance imaging
*DIMETHYL fumarate
Language
ISSN
1352-4585
Abstract
We investigated the impact of disease-modifying therapies (DMTs) on the evolving tissue damage in iron rim multiple sclerosis lesions using a novel post-processing magnetic resonance imaging (MRI) approach, the T1/T2 ratio. In this study, on baseline and 1-year follow-up, T1/T2 ratios of iron rim lesions (IRLs) in patients starting DMT (dimethyl fumarate, fingolimod, ocrelizumab) did not statistically differ compared to patients without DMT. At the second follow-up, T1/T2 ratios were significantly lower in IRLs in patients without DMT (p = 0.002), suggesting that DMTs have a beneficial delayed effect on lesion evolution and tissue matrix damage in IRLs. [ABSTRACT FROM AUTHOR]